Navigation Links
Vista Partners Updates Coverage; Maintains $3.20 Target Price
Date:10/13/2008

LOS ANGELES, Oct. 13 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationally continue to increase and sales from the Company's lab alliance, which give ABMC's products exposure in numerous testing centers, continue to increase as well. The Company recently received CLIA approval from the FDA. The CLIA approval will significantly broaden the Company's customer base and we believe ABMC's valuation will increase dramatically in the near future."

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About American Bio Medica Corporation:

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(R) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

Contact:

Vista Partners LLC

Jorden Lampos

(310) 744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics Posts Letter to Stockholders on Web Site
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
9. Vista Partners Updates Coverage; Maintains $3.20 Target Price
10. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
11. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:2/22/2017)...  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Biocom Global Life Science Partnering Conference.  The presentation will ... the Torrey Pines Lodge, in San Diego.  ... who have chosen our company, amongst numerous others, to ... and clinical researchers," said Mr. Chen. "In contrast to ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider of educational ... is pleased to announce the launch of a new scholarship for young scientists seeking ... This merit-based scholarship is open to all high school seniors, 17 years or older; ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... the addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, ... Pennside. , Perkins joins Pennside after more than a decade with leading ...
Breaking Biology Technology:
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):